Work

Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study

Year: 2025

Type: article

Abstract: Background: early-stage breast cancer is improved by the use of CDK4/6 inhibitors. However, to date, minimal data are available on their safety and effectiveness in older patients (≥70 years old). Methods: A retrospective, multi-centre cohort study was conducted in two oncology centres in Pavia, Italy. Patients had to have received at least 3 months of therapy with adjuvant abemaciclib (a CDK4/6 inhibitor). Data on demographics, toxicity, dose reductions and clinical outcomes were analysed. Analyses were descriptive, with continuous variables reported as median (IQR) and categorical variables as counts and percentages. Results: 8.3 months). Toxicities were generally of low-moderate grade and manageable. Conclusion: During adjuvant abemaciclib, low-moderate-grade toxicities were common, particularly haematological and gastrointestinal events. Older patients showed a numerically higher rate of dose reductions, suggesting a potential need for personalized dosing and early monitoring in this subgroup. These findings should be considered hypothesis-generating and warrant confirmation in larger prospective studies.

Source: Drugs in Context

DOI: 10.7573/dic.2025-7-5